Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

l-DOPA administration enhances 6-hydroxydopamine generation.

Himant Maharaj1, Deepa Sukhdev Maharaj, Mark Scheepers

  • 1Division of Pharmacology, Faculty of Pharmacy, Rhodes University, P.O. Box 94, Grahamstown, 6139, South Africa.

Brain Research
|November 1, 2005
PubMed
Summary

Parkinson's disease patients treated with L-DOPA may develop neurotoxicity due to the formation of 6-hydroxydopamine (6-OHDA) when L-DOPA interacts with iron. Antioxidants like melatonin may mitigate this L-DOPA-induced neurotoxicity.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mortality risk in adults with intellectual disabilities and epilepsy: an England and Wales case-control study.

Journal of neurology·2023
Same author

Correction to: Epilepsy related multimorbidity, polypharmacy and risks in adults with intellectual disabilities: a national study.

Journal of neurology·2022
Same author

Epilepsy related multimorbidity, polypharmacy and risks in adults with intellectual disabilities: a national study.

Journal of neurology·2022
Same author

COVID-19 deaths in people with intellectual disability in the UK and Ireland: descriptive study.

BJPsych open·2020
Same author

Quality improvement in the management of people with epilepsy and intellectual disability: the development of clinical guidance.

Expert opinion on pharmacotherapy·2019
Same author

Acyclovir inhibits rat liver tryptophan-2,3-dioxygenase and induces a concomitant rise in brain serotonin and 5-hydroxyindole acetic acid levels.

Metabolic brain disease·2008

Area of Science:

  • Neuroscience
  • Pharmacology
  • Biochemistry

Background:

  • L-3,4-dihydroxyphenylalanine (L-DOPA) is a primary treatment for Parkinson's disease (PD).
  • Patient tolerance and side effects limit L-DOPA efficacy, necessitating higher dosages.
  • The potential neurotoxic mechanisms of L-DOPA, particularly its interaction with iron, require further investigation.

Purpose of the Study:

  • To determine if dopamine (DA) reacts with iron to form the neurotoxin 6-hydroxydopamine (6-OHDA).
  • To investigate L-DOPA's role in endogenous 6-OHDA formation and its interaction with iron in rat models.
  • To assess the neuroprotective potential of melatonin against L-DOPA-induced toxicity.

Main Methods:

  • In vitro and in vivo studies involving L-DOPA treatment in rats.

Related Experiment Videos

  • Measurement of 6-OHDA formation and lipid peroxidation in rat striatum.
  • Assessment of melatonin's effect on free radical activity and 6-OHDA levels.

    • Main Results:

    • Dopamine (DA) was confirmed to react with iron, forming 6-OHDA.
    • L-DOPA treatment in rats led to endogenous 6-OHDA formation and enhanced iron-induced lipid peroxidation.
    • Melatonin significantly reduced L-DOPA-stimulated 6-OHDA formation in the rat striatum.

    Conclusions:

    • L-DOPA treatment can induce neurotoxicity through 6-OHDA formation, especially in the presence of iron.
    • Concomitant administration of antioxidants, such as melatonin, may improve L-DOPA therapy longevity in Parkinson's disease patients.
    • This study highlights a critical mechanism of L-DOPA-induced neurotoxicity, suggesting therapeutic modifications.